Ovarian cancer patient is first to receive new therapy targeting Mage-A4 protein | PiQ Markets
Ovarian cancer patient is first to receive new therapy targeting Mage-A4 protein
2 sources↑ Market-relevant2 events
IN SHORT
Tracy Tomlinson, 58, has become the first patient globally to receive a pioneering new therapy, ZI-MA4-1, at the Christie NHS Foundation Trust in Manchester. The treatment, part of a clinical trial, engineers T-cell receptors to target tumours producing the Mage-A4 protein.
✉Newsletter
PiQ Daily
Pick your topics. Get only what matters, on your cadence.
Key Numbers
58age of patient Tracy Tomlinson
2020year of diagnosis for Tracy Tomlinson
Who's Involved
Tracy Tomlinson
58-year-old ovarian cancer patient, first to receive ZI-MA4-1 therapy
Christie NHS Foundation Trust
Location of the clinical trial and administration of the new therapy
Mage-A4
Protein targeted by the new cancer therapy
↳ Why This Matters
This marks a significant advancement in cancer treatment, offering a new therapeutic approach that harnesses the immune system to target specific cancer proteins, potentially providing hope for patients with limited options.
Key facts
Tracy Tomlinson, 58, has become the first patient in the world to receive a pioneering new therapy.
The experimental drug, ZI-MA4-1, was administered at the Christie NHS Foundation Trust in Manchester.
The treatment is part of a clinical trial for ovarian, lung, sarcomas, and head and neck cancers.
The therapy combines natural killer (NK) cells with engineered T-cell receptors targeting the Mage-A4 protein.
Mage-A4 is present in various cancers and is considered a suitable target for attacking abnormal cells.
Tracy Tomlinson, a 58-year-old woman living with advanced ovarian cancer, has become the first patient worldwide to receive a novel experimental therapy known as ZI-MA4-1. The treatment was administered at the Christie NHS Foundation Trust in Manchester as part of a clinical trial.
The trial aims to evaluate the drug's effectiveness across multiple cancer types, including ovarian, lung, sarcomas, and head and neck cancers. Tomlinson has been living with ovarian cancer since her diagnosis in 2020 and has previously undergone surgery and chemotherapy.
The ZI-MA4-1 therapy works by integrating two key mechanisms: it utilizes the body's natural killer (NK) cells, which are specialized immune cells designed to destroy abnormal cells, and employs engineered T-cell receptors (TCRs) to specifically recognize and target tumors that produce the Mage-A4 protein. Experts believe Mage-A4 is an ideal target for attacking cancerous cells, as it is found in several types of cancer.
Frequently asked questions
Tracy Tomlinson is a 58-year-old patient with advanced ovarian cancer who has become the first person in the world to receive the experimental drug ZI-MA4-1.
ZI-MA4-1 is a pioneering new therapy being evaluated in a clinical trial. It works by combining natural killer (NK) cells with engineered T-cell receptors to target tumors producing the Mage-A4 protein.
The clinical trial is evaluating the efficacy of ZI-MA4-1 for ovarian, lung, sarcomas, and head and neck cancers.
What Happens Next
01Chris Jones will be scanned in six weeks to assess the vaccine's effectiveness.
02The trial will continue to evaluate the efficacy of ZI-MA4-1 for several cancer types.
Get the newsletter.
Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.
Cadence
How It Developed
Tracy Tomlinson, 58, was the first patient globally to receive a new experimental drug, ZI-MA4-1.
The treatment is part of a clinical trial evaluating its efficacy for several cancer types, including ovarian, lung, sarcomas, and head and neck cancer.
The therapy harnesses natural killer (NK) cells and engineers T-cell receptors to target tumours producing the Mage-A4 protein.
Mage-A4 is found in several types of cancer and is believed to be an ideal target for attacking abnormal cells.
